Aprea Therapeutics provides 2024 pipeline update: ATRN-119 dose escalation ongoing, IND for APR-1051 expected Q1 2024

Aprea Therapeutics, Inc.

Phase 1/2a trial of ATRN-119 continues; two patients achieved stable disease at 50 mg and 200 mg doses.
Dose-limiting toxicity period for 350 mg cohort completed; RP2D expected H2 2024.
IND submission for next-gen WEE1 inhibitor APR-1051 being finalized; FDA clearance expected Q1 2024.
Preclinical data for APR-1051 show improved selectivity and reduced off-target effects vs other WEE1 inhibitors.
Company to hold investor meetings at LifeSci Partners Corporate Access Event on Jan 10, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.